Biopharma Serentis raises £10.3m in series A funding

Serentis Ltd, the Cambridge Science Park-based biopharma, completed a £10.3m Series A financing round.

The investment was jointly led by Life Science venture funds, MVM Life Science Partners LLP, Apposite Capital LLP and Novo A/S.

Established in 2006, Serentis, which has expertise in product discovery and development, will use the funds to progress its lead products into clinical-stage proof-of-principle trials and to expand its development pipeline. Pipeline products will be identified via Serentis' internal discovery activities and by licensing near-clinical stage assets and technologies.

CEO and Serentis co-founder Tim Sharpington: "The funds raised will … enable the company to further build its management team and to develop both its internal programs and licensing activities and thereby rapidly build a robust clinical-stage pipeline".

Dr Martin Murphy, Chairman and Partner at MVM Life Science said: "The management team at Serentis have an impressive track record of innovating and developing low-risk development compounds which can be rapidly progressed to proof-of-principle studies."

Serentis Inc is privately owned and incorporated in Delaware. Its operating arm, Serentis Ltd, based in Cambridge, is developing a pipeline of products initially focussed in the areas of wound care/dermatology and cancer supportive care with additional research programmes in fibrotic disease and diabetic complications.

The company intends to use its core development skills by licensing near-clinical stage products and technologies. Its development model is based on a fast to proof-of-principle approach.

Dr Martin Murphy (MVM Life Science Partners LLP), Dr Allan Marchington (Apposite Capital LLP) and Dr Martin Edwards (Novo A/S) have joined the board of Serentis.

4th July 2007



Previous articles
News from Silicon Fen: Marshall partners with Plasan for armour; PneumaCare trials mobile lung scan; ipaccess boosts wireless
Cronto targets early pilot trials for its secure verification platform for e-business
NATO won over by Autonomy's IDOL
Meldex reports strong revenue growth, narrowed pre-tax loss in ’07; market disappointed
NXT shift of product design ops to Hong Kong to slow earnings
Ubisense, a 'company to watch in 2006'
Babraham Bioscience ties up funding for Bioincubator with EEDA injection
Stock Market warms to Cybit’s revenue, profit gains in 08/09
Autonomy launches iPhone app for legal eagles
Enval closes series ‘A’ funding round
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • Cambridge Consultants


Mammen Eapen
Chief Financial Officer


Cambridge Consultants has iconic status in Silicon Fen as one of the catalysts for growth of the Cambridge Cluster. For over 40 years it has helped clients turn business opportunities into commercial successes, whether launching first-to-market products, entering new markets or expanding existing markets

[Cambridge Consultants's profile]


Top20 Index




Currently: 161.56